Direxion Daily S&P Biotech Bear 3X ETF
LABD
17 hedge funds and large institutions have $26.5M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 1 closing their positions.
127% more call options, than puts
Call options by funds: $20M | Put options by funds: $8.79M
53% more capital invested
Capital invested by funds: $17.3M → $26.5M (+$9.17M)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
3.23% less ownership
Funds ownership: 41.58% → 38.35% (-3.2%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$4.64M |
| 2 |
SCM
Southport Capital Management
Chattanooga,
Tennessee
|
+$1.63M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.2M |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$374K |
| 5 |
Jane Street
New York
|
+$272K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.18M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.46M |
| 3 |
VF
Virtu Financial
New York
|
-$453K |
| 4 |
Goldman Sachs
New York
|
-$288K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
-$266K |
LABD Hedge Fund Activity: Q1 2022 in Review
17 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2022, worth a combined $26.5M — up 53% from $17.3M a quarter earlier.
Fund positioning in LABD was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 7 added to existing stakes and 9 trimmed.
The largest buyer was HRT Financial, adding an estimated $4.64M. The largest seller was Susquehanna International Group, cutting an estimated $2.18M.
- 17 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $26.5M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2022, up 53% quarter-over-quarter.
- 1 fund opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2022 was HRT Financial, an estimated $4.64M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2022 was Susquehanna International Group, an estimated $2.18M sold.
Based on aggregated 13F filings for Q1 2022.